Daniel Davis Joins Instylla's Board of Directors to Drive Innovation in Embolic Solutions

Instylla Welcomes Daniel Davis to the Board of Directors

Instylla, Inc., a private company based in Bedford, Massachusetts, specializing in innovative solutions for peripheral vascular embolization, has revealed the addition of Daniel Davis to its Board of Directors. This strategic move is expected to enhance the company's direction as it prepares for pivotal advancements in its embolic systems.

Daniel Davis currently serves as the Chief Strategy Officer at Imperative Care, a company he has been with since 2020. In this role, Davis has driven growth and development surrounding stroke and vascular technologies, gathering over 25 years of experience in sales, marketing, and business development within both early-stage and Fortune 500 medical device enterprises. Prior to his position at Imperative Care, he held significant roles including Chief Commercial Officer and President of North America at Penumbra, Inc. His leadership there was instrumental in the introduction of embolization and mechanical thrombectomy technologies focused on neurovascular and peripheral applications.

Amar Sawhney, Chairman and CEO of Instylla, expressed enthusiasm about Davis's appointment, stating, "We are very pleased to welcome Daniel Davis to the Board at Instylla. Daniel's incisive leadership and deep industry experience will be a strong match for our Board as we drive commercialization for our next-generation liquid embolics."

Davis himself also shared his excitement regarding his new role at Instylla, emphasizing the significant opportunity to impact patient care through innovative technology. "I look forward to joining the Instylla Board of Directors at such a pivotal time, as the company advances the Embrace™ Hydrogel Embolic System toward commercialization and brings the Tembo™ Embolic System to market. Instylla has introduced innovations that have the potential to transform treatments and outcomes, and I am honored to join Amar and the leadership team at this exciting time in the company's growth," he remarked.

Instylla focuses on developing novel resorbable embolic agents aimed at advancing interventional radiology, initially targeting clinical applications in interventional oncology and peripheral vasculature. Founded in 2017 by Incept LLC, the company is backed by several notable venture capital groups.

As Instylla continues its pioneering work, the appointment of Daniel Davis is poised to align the company's efforts with industry best practices and lead to significant advancements in their product offerings. With the Embrace and Tembo systems in focus, Instylla aims to innovate and improve therapeutic outcomes for patients worldwide.

For those interested in learning more about Instylla and its advancements in medical technology, additional information can be found at Instylla's website.

Caution: The Embrace HES is currently an investigational device, limited by federal law to investigational use only, and is not available for sale.